{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:49:39Z","timestamp":1790401779123,"version":"4.1.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T00:00:00Z","timestamp":1549324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL121363"],"award-info":[{"award-number":["HL121363"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL131862"],"award-info":[{"award-number":["HL131862"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1093\/cvr\/cvz025","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T15:17:04Z","timestamp":1549293424000},"page":"869-877","source":"Crossref","is-referenced-by-count":110,"title":["T cell checkpoint regulators in the heart"],"prefix":"10.1093","volume":"115","author":[{"given":"Nir","family":"Grabie","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, NRB Room 752N, 77 Avenue Louis Pasteur, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H","family":"Lichtman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, NRB Room 752N, 77 Avenue Louis Pasteur, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Padera","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, NRB Room 752N, 77 Avenue Louis Pasteur, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,5]]},"reference":[{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B1","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1152\/physrev.00068.2017","article-title":"Macrophages and cardiovascular health","volume":"98","author":"Frodermann","year":"2018","journal-title":"Physiol Rev"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.2009.00784.x","article-title":"Mechanisms of costimulation","volume":"229","author":"Sharpe","year":"2009","journal-title":"Immunol Rev"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.08.007","article-title":"A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity","volume":"95","author":"Kumar","year":"2018","journal-title":"J Autoimmun"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","article-title":"Coinhibitory pathways in the B7-CD28 ligand-receptor family","volume":"44","author":"Schildberg","year":"2016","journal-title":"Immunity"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B6","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.4049\/jimmunol.0802610","article-title":"Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice","volume":"183","author":"Araki","year":"2009","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0165-2478(02)00142-6","article-title":"Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues","volume":"84","author":"Ishida","year":"2002","journal-title":"Immunol Lett"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"LAG-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B12","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","article-title":"LAG-3 inhibits the activation of CD4(+) T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII","volume":"19","author":"Maruhashi","year":"2018","journal-title":"Nat Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/2326-6066.CIR-16-0193","article-title":"Regulatory T cells: differentiation and function","volume":"4","author":"Plitas","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.it.2011.06.002","article-title":"Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation","volume":"32","author":"Wing","year":"2011","journal-title":"Trends Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41401-018-0062-2","article-title":"Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J Leukoc Biol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B17","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B18","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B21","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/2326-6066.CIR-18-0487","article-title":"The balancing act between cancer immunity and autoimmunity in response to immunotherapy","volume":"6","author":"Young","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B22","doi-asserted-by":"crossref","first-page":"933.","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B24","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1002\/eji.200324270","article-title":"Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis","volume":"33","author":"Rodig","year":"2003","journal-title":"Eur J Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1172\/JCI200316867","article-title":"IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis","volume":"111","author":"Grabie","year":"2003","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B26","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B27","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B28","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B31","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B32","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.106.635664","article-title":"Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium","volume":"114","author":"Goser","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B33","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.20100466","article-title":"PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice","volume":"208","author":"Okazaki","year":"2011","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4049\/jimmunol.167.1.140","article-title":"CD28-independent costimulation of T cells in alloimmune responses","volume":"167","author":"Yamada","year":"2001","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B38","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.4049\/jimmunol.158.11.5091","article-title":"CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice","volume":"158","author":"Tivol","year":"1997","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1074-7613(01)00097-8","article-title":"CTLA-4 regulates induction of anergy in vivo","volume":"14","author":"Greenwald","year":"2001","journal-title":"Immunity"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ni.1835","article-title":"CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms","volume":"11","author":"Ise","year":"2010","journal-title":"Nat Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B42","doi-asserted-by":"crossref","first-page":"e96378","DOI":"10.1172\/jci.insight.96378","article-title":"Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival","volume":"3","author":"Liu","year":"2018","journal-title":"JCI Insight"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B43","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","article-title":"CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes","volume":"101","author":"Love","year":"2007","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B44","doi-asserted-by":"crossref","first-page":"e000247.","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B45","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0065-2776(08)00604-4","article-title":"Pathogenesis of myocarditis and dilated cardiomyopathy","volume":"99","author":"Cihakova","year":"2008","journal-title":"Adv Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B47","doi-asserted-by":"crossref","first-page":"30.","DOI":"10.1007\/s11892-015-0598-1","article-title":"Cardiac autoimmunity as a novel biomarker, mediator, and therapeutic target of heart disease in type 1 diabetes","volume":"15","author":"Lipes","year":"2015","journal-title":"Curr Diab Rep"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B48","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/BOR.0b013e3283620036","article-title":"Autoimmunity in viral myocarditis","volume":"25","author":"Reddy","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tcm.2012.07.005","article-title":"Role of impaired central tolerance to alpha-myosin in inflammatory heart disease","volume":"22","author":"Lv","year":"2012","journal-title":"Trends Cardiovasc Med"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B50","doi-asserted-by":"crossref","first-page":"138ra180","DOI":"10.1126\/scitranslmed.3003551","article-title":"Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes","volume":"4","author":"Gottumukkala","year":"2012","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B51","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1172\/JCI44583","article-title":"Impaired thymic tolerance to alpha-myosin directs autoimmunity to the heart in mice and humans","volume":"121","author":"Lv","year":"2011","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B52","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B54","doi-asserted-by":"crossref","first-page":"812.e1","DOI":"10.1016\/j.cjca.2018.03.007","article-title":"Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab","volume":"34","author":"Yamaguchi","year":"2018","journal-title":"Can J Cardiol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B55","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B56","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","article-title":"Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area","volume":"34","author":"Mir","year":"2018","journal-title":"Can J Cardiol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B57","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.jtho.2018.10.156","article-title":"Fulminant myocarditis caused by an immune checkpoint inhibitor: a case report with pathological findings","volume":"14","author":"Imai","year":"2019","journal-title":"J Thorac Oncol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B58","doi-asserted-by":"crossref","first-page":"13.","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B59","doi-asserted-by":"crossref","first-page":"e1361097.","DOI":"10.1080\/2162402X.2017.1361097","article-title":"Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab","volume":"6","author":"Reuben","year":"2017","journal-title":"Oncoimmunology"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B60","doi-asserted-by":"crossref","first-page":"91.","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B61","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.4049\/jimmunol.179.8.5204","article-title":"PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection","volume":"179","author":"Tanaka","year":"2007","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B62","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/eji.200737583","article-title":"Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance","volume":"37","author":"Wang","year":"2007","journal-title":"Eur J Immunol"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B63","doi-asserted-by":"crossref","first-page":"MMT10.","DOI":"10.2217\/mmt-2018-0004","article-title":"Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations","volume":"5","author":"Grant","year":"2018","journal-title":"Melanoma Manag"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-016-1918-2","article-title":"Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report","volume":"66","author":"Owonikoko","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B65","doi-asserted-by":"crossref","first-page":"e003688.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003688","article-title":"Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure","volume":"10","author":"Bansal","year":"2017","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t2019040805031461600_cvz025-B66","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/CIRCHEARTFAILURE.115.002225","article-title":"Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure","volume":"8","author":"Nevers","year":"2015","journal-title":"Circ Heart Fail"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/115\/5\/869\/28283295\/cvz025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T07:29:24Z","timestamp":1694590164000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/115\/5\/869\/5307034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,5]]},"references-count":66,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,2,5]]},"published-print":{"date-parts":[[2019,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvz025","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,15]]},"published":{"date-parts":[[2019,2,5]]}}}